Please ensure Javascript is enabled for purposes of website accessibility

Pfizer Breast Cancer Drug Posts "Disappointing" Results in Clinical Trials

By Eric Volkman – May 31, 2020 at 9:19AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Despite the setback, Pfizer maintains its revenue growth projections.

One of Pfizer's (PFE 0.41%) blockbuster drugs has effectively flopped in a late-stage combination therapy trial. The company announced on Friday that the results of a Phase 3 trial for its Ibrance (Palbociclib) breast cancer drug in the treatment of early stage breast cancer were disappointing.

The results of the study indicate that, when used in combination with post-surgery endocrine therapy, it "is unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival (iDFS)."

The trial was conducted on male and female patients with HR-positive, HER2-negative early stage breast cancer.

Cancer attacking an organism.

Image source: Getty Images.

This is a quite a setback for Pfizer, which had hoped to unlock even greater commercial potential for the successful Ibrance in early stage breast cancer treatment. It said it was "disappointed" in the study's results.

In spite of that, the pharmaceutical giant insists that the Ibrance setback won't divert it from its growth path. In its pres release announcing the news, the company wrote that "[g]iven the continued breadth of our marketed portfolio and strength of our pipeline, our growth projections are not reliant upon any individual marketed medicine or pipeline opportunity."

Pfizer added that it still believes it will be able to produce a compound annual growth rate of 6%, at a minimum, through 2025. Ibrance should continue to be a significant factor in that; in the company's first quarter of fiscal 2020, revenue for the drug in the U.S. and emerging markets grew by 17% on a year-over-year basis. 

Investors weren't taking the latest news on Ibrance well, however. At one point, Pfizer's shares sank by 6% in after-hours trading following the announcement on Friday; this was a steeper fall than that suffered by the broader stock market during the day.

 

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$44.34 (0.41%) $0.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
104%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.